Drug 1: Dolutegravir (DTG)

Drug 2: Rilpivirine (RPV)

Eligibility: Patients who had undectable viral load for at least 6 months are eligible to be on this regimen

Drug 1: Dolutegravir (DTG)

Drug 2: Lamivudine (3TC)

Eligibility: Patients who are treatment naïve or who had undetectable viral load for ≥6 months on a TAF regimen are eligible to be on this regimen

Drug 1: Dolutegravir (DTG)

Drug 2: Darunavir (DRV)

Drug 3: cobicistat [c]

Eligibility: Patients who have poor renal function or severe lipoatrophy

Oral lead-in for ≥ 28 days and then IM monthly injections

Drug 1: Cabotegravir (CAB)

Drug 2: Rilpivirine (RPV)

Eligibility: NON-FORMULARY at Scripps Healthcare. Pharmacist to do the following:

• Verify when last dose received (PO lead-in or IM maintenance at clinic)
• If monthly IM injection is missed or delayed by > 7 days while inpatient or on oral lead-in regimen, then assess oral available options at Scripps (unable to provide oral cabotegravir as only available from a single specialty pharmacy).
• Alternative options include (not limited to): (1) bridge with patient’s pre-Cabenuva oral HIV regimen; (2) Dolutegravir + Rilpivirine (note: diet restrictions and drug-drug interactions with rilpivirine).
• Inform outpatient HIV provider of bridging therapy so that appropriate re-initiation of Cabenuva can be done by outpatient HIV provider

For any questions, contact ID pharmacist

Drug 1: Tenofovir Disoproxil Fumarate (TDF)

Drug 2: Emtricitabine (FTC)

Drug 1: Tenofovir Alafenamide (TAF)

Drug 2: Emtricitabine (FTC)

• Other regimens to assist with HIV viral load suppression include
  • Triumeq® + Prezcobix®
  • Biktarvy® + Prezcobix®
• Verify with patient’s HIV clinic and/or consult ID pharmacist

1. U.S. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. 2018 Oct 25.
2. Centers for Disease Control and Prevention. Pre-exposure Prophylaxis for the Prevention of HIV infection in the United States – 2017 Update Clinical Practice Guideline. 2017.